George W. Elgart, Terri L. Meinking

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Ivermectin is a potent antiparasitic drug and the first commercially available member of a new class of drugs (macrocyclic lactones) that has been approved for human use. Ivermectin has already proven to be highly effective in the elimination of river blindness as a public health burden. Side effects have been minor, and patient acceptance is good. Promising results in off-label applications for ectoparasitic infestations are increasingly important as resistance to topical therapy becomes more prevalent. Ivermectin represents an advance in the therapeutic armamentarium and should be considered in appropriate cases.

Original languageEnglish (US)
Pages (from-to)277-282
Number of pages6
JournalDermatologic Clinics
Issue number2
StatePublished - Apr 2003

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Ivermectin'. Together they form a unique fingerprint.

Cite this